Vancouver-based Cardiome Pharma Corp. (TSX: COM), Allon Therapeutics Inc. (TSX: NPC) and EnWave Corp. (TSX-V: ENW) have won Gold Leaf awards from Canada’s national biotechnology industry organization, BIOTECanada.
Cardiome was recognized as company of the year, while Allon and EnWave have won as early stage companies of the year in the health and industrial categories, respectively.
According to a press release from Allon, the company’s award recognizes its clinical trial successes and progress toward commercializing products for degenerative brain diseases such as Alzheimer’s, Parkinson’s and several types of frontotemporal dementia.
EnWave’s award recognizes the company’s technologies, which dehydrate live or active materials such as antibodies, bacteria, enzymes and viruses in sterile vials to produce shelf-stable pharmaceuticals for humans and animals, along with non-regulated biological products such as reagents.
“This award recognizes our early successes in drying vaccines and other biomaterials and encourages our mission to see more shelf-stable medicines made available to developing countries where constant refrigeration is not available,” EnWave chairman and co-CEO Tim Durance said in a press release.
Cardiome is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Calls to the company for details about the win were not returned by press deadline.
Jenny Wagler
Twitter: JennyWagler_BIV